| 1 | Study | 3.48% | |
| 2 | Cancer | 0.95% | |
| 3 | New | 0.95% | |
| 4 | Asia | 0.95% | |
| 5 | Researchers | 0.95% | |
| 6 | Patients | 0.63% | |
| 7 | mRNA | 0.63% | |
| 8 | Risk | 0.63% | |
| 9 | Screens | 0.63% | |
| 10 | Safety | 0.63% | |
| 11 | Therapy | 0.63% | |
| 12 | Kidney | 0.63% | |
| 13 | COVID-19 | 0.63% | |
| 14 | Artery | 0.63% | |
| 15 | Care | 0.63% | |
| 16 | Brain | 0.63% | |
| 17 | Pacific | 0.63% | |
| 18 | COPD | 0.63% | |
| 19 | Cell | 0.63% | |
| 20 | Tertiary | 0.63% | |
| 21 | Era | 0.63% | |
| 22 | LivaNova’s | 0.32% | |
| 23 | Some | 0.32% | |
| 24 | Pathogen | 0.32% | |
| 25 | Effectively | 0.32% | |
| 26 | Strategies | 0.32% | |
| 27 | Endocrine | 0.32% | |
| 28 | Cardiobacterium | 0.32% | |
| 29 | Guillain-Barre | 0.32% | |
| 30 | Approval | 0.32% | |
| 31 | Office | 0.32% | |
| 32 | Investigational | 0.32% | |
| 33 | Effectiveness | 0.32% | |
| 34 | Their | 0.32% | |
| 35 | Resistance | 0.32% | |
| 36 | Day | 0.32% | |
| 37 | CKD | 0.32% | |
| 38 | Detection | 0.32% | |
| 39 | NR2F2 | 0.32% | |
| 40 | Syndrome | 0.32% | |
| 41 | Drug | 0.32% | |
| 42 | Dental | 0.32% | |
| 43 | Fibrosis | 0.32% | |
| 44 | Sabah | 0.32% | |
| 45 | Infection | 0.32% | |
| 46 | Predicts | 0.32% | |
| 47 | Inhibitor | 0.32% | |
| 48 | CooperVision | 0.32% | |
| 49 | Hospital | 0.32% | |
| 50 | Transplant | 0.32% | |
|
는 분류, 데이터 기준으로 의 기사에서 의 고유명사 데이터를 통해 생성되었습니다.
|
|||